Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Marc Baay, Kaatje Bollaerts, Claudio Struchiner & Thomas Verstraeten. (2017) Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines & Immunotherapeutics 13:8, pages 1916-1920.
Read now
Read now
Natalie G Martin & Matthew D Snape. (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?. Expert Review of Vaccines 12:8, pages 837-858.
Read now
Read now
Koen B. Pouwels, Eelko Hak, Arie van der Ende, Hannah Christensen, Germie P.J.M. van den Dobbelsteen & Maarten J. Postma. (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Human Vaccines & Immunotherapeutics 9:5, pages 1129-1138.
Read now
Read now
Articles from other publishers (25)
Helen Petousis-Harris. (2020) Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Safety 43:12, pages 1205-1210.
Crossref
Crossref
Gaston De Serres, Marie-Noëlle Billard, Marie-Claude Gariépy, Marie-Claude Roy, François D. Boucher, Hélène Gagné, Sylvie Belley, Eveline Toth, Monique Landry & Danuta M. Skowronski. (2019) Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal. Vaccine 37:35, pages 4996-5002.
Crossref
Crossref
Dan M. Granoff, Andrew J. Pollard & Lee H. Harrison. 2018. Plotkin's Vaccines. Plotkin's Vaccines
644
662.e6
.
Linny Kimly Phuong, Caterina Bonetto, Jim Buttery, Yolanda Brauchli Pernus, Rebecca Chandler, Patrizia Felicetti, Karen L. Goldenthal, Merita Kucuku, Giuseppe Monaco, Barbara Pahud, Stanford T. Shulman, Karina A. Top, Francesco Trotta, Rolando Ulloa-Gutierrez, Frederick Varricchio, Sarah de Ferranti, Jane W. Newburger, Nagib Dahdah, Surjit Singh, Jan Bonhoeffer & David Burgner. (2017) Kawasaki disease and immunisation: A systematic review. Vaccine 35:14, pages 1770-1779.
Crossref
Crossref
Gary M. Ginsberg, Colin Block & Chen Stein-Zamir. (2016) Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. International Journal of Public Health 61:6, pages 683-692.
Crossref
Crossref
Helen Marshall, Bing Wang, Steve Wesselingh, Matthew Snape & Andrew J. Pollard. (2016) Control of invasive meningococcal disease. International Journal of Evidence-Based Healthcare 14:1, pages 3-14.
Crossref
Crossref
Andreia Leite, Nick J. Andrews & Sara L. Thomas. (2016) Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods. Pharmacoepidemiology and Drug Safety 25:3, pages 225-237.
Crossref
Crossref
Marcello Tirani, Michela Meregaglia & Alessia Melegaro. (2015) Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. PLOS ONE 10:4, pages e0123383.
Crossref
Crossref
Avishay Sarfatti & Simon Nadel. (2014) How important is the meningococcal B vaccine?. Clinical Practice 11:6, pages 555-558.
Crossref
Crossref
Hannah Christensen, Matthew Hickman, W. John Edmunds & Caroline L. Trotter. (2013) Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine 31:23, pages 2638-2646.
Crossref
Crossref
Dan M. Granoff. (2013) Commentary. Pediatric Infectious Disease Journal 32:4, pages 372-373.
Crossref
Crossref
Nicole M. Caesar, Kenneth A. Myers & Xin Fan. (2013) Neisseria meningitidis serogroup B vaccine development. Microbial Pathogenesis 57, pages 33-40.
Crossref
Crossref
Timo Vesikari, Susanna Esposito, Roman Prymula, Ellen Ypma, Igor Kohl, Daniela Toneatto, Peter Dull & Alan Kimura. (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. The Lancet 381:9869, pages 825-835.
Crossref
Crossref
Johan Holst, Hanne Nøkleby & Julie A. Bettinger. (2012) Considerations for controlling invasive meningococcal disease in high income countries. Vaccine 30, pages B57-B62.
Crossref
Crossref
Diana Lennon, Stewart Reid, Joanna Stewart, Catherine Jackson, Sue Crengle & Teuila Percival. (2012) Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic. Journal of Paediatrics and Child Health 48:3, pages 193-201.
Crossref
Crossref
Robert T. Chen, Jason M. Glanz & Claudia Vellozzi. 2012. Pharmacoepidemiology. Pharmacoepidemiology
423
468
.
María Elena Santolaya, Miguel L O'Ryan, María Teresa Valenzuela, Valeria Prado, Rodrigo Vergara, Alma Muñoz, Daniela Toneatto, Gabriela Graña, Huajun Wang, Ralf Clemens & Peter M Dull. (2012) Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. The Lancet 379:9816, pages 617-624.
Crossref
Crossref
Michael J. GoodmanJames D. NordinEdward A. BelongiaJohn P. Mullooly & James Baggs. (2010) Henoch-Schönlein Purpura and Polysaccharide Meningococcal Vaccine. Pediatrics 126:2, pages e325-e329.
Crossref
Crossref
Steven Black, Juhani Eskola, Claire-Anne Siegrist, Neal Halsey, Noni MacDonald, Barbara Law, Elizabeth Miller, Nick Andrews, Julia Stowe, Daniel Salmon, Kirsten Vannice, Hector S Izurieta, Aysha Akhtar, Mike Gold, Gabriel Oselka, Patrick Zuber, Dina Pfeifer & Claudia Vellozzi. (2009) Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. The Lancet 374:9707, pages 2115-2122.
Crossref
Crossref
Johan Holst, Diana Martin, Richard Arnold, Concepcion Campa Huergo, Philipp Oster, Jane O’Hallahan & Einar Rosenqvist. (2009) Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27, pages B3-B12.
Crossref
Crossref
. (2009) IMPACT après 17 ans : Des leçons apprises au sujet d'un réseautage réussi. Paediatrics & Child Health 14:1, pages 36-39.
Crossref
Crossref
. (2009) IMPACT after 17 years: Lessons learned about successful networking. Paediatrics & Child Health 14:1, pages 33-35.
Crossref
Crossref
Michael V. Tatley, Desireé L. Kunac, Anne McNicholas, Lifeng Zhou, Suzie Ballantyne, Janelle Ashton, Paul Stehr-Green, Yvonne Galloway & Stewart Reid. (2008) The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine 26:22, pages 2746-2752.
Crossref
Crossref
Paul Stehr-Green, Sarah Radke, Charlotte Kieft, Yvonne Galloway, Anne McNicholas & Stewart Reid. (2008) The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 26:6, pages 739-742.
Crossref
Crossref
Barbara Baudner & Rino Rappuoli. 2008. Immunity Against Mucosal Pathogens. Immunity Against Mucosal Pathogens
323
365
.